HiPS-RTT_CUH01	
    			    			
                BRCi024-A            
            
        General
Cell Line | 
					|
| hPSCreg name | BRCi024-A | 
| Cite as: | BRCi024-A (RRID:CVCL_D6S1) | 
| Alternative name(s) | 
									 
	HiPS-RTT_CUH01	 
							 | 
						
| Cell line type | Human induced pluripotent stem cell (hiPSC) | 
| Similar lines | 
							 | 
					
| Last update | 14th March 2024 | 
| User feedback | |
Provider | 
					|
| Generator | RIKEN BioResource Research Center (BRC) | 
External Databases | 
						|
| BioSamples | SAMEA115396857 | 
| Cellosaurus | CVCL_D6S1 | 
							    
							General Information | 
					|
| Publications | |
| * Is the cell line readily obtainable for third parties? | 
                                     Yes                                                                                 Research use: allowed 
                                                                                    Clinical use: not allowed 
                                                                                    Commercial use: not allowed 
                                                                         | 
                            
Donor Information
General Donor Information | 
					|
| Sex | female | 
| Ethnicity | Japanese | 
Phenotype and Disease related information (Donor) | 
					|
| Diseases | A disease was diagnosed.
																	 | 
					
| Disease associated phenotypes | 
								
  | 
						
Karyotyping (Donor) | 
						|
| Has the donor karyotype been analysed? | 
								 No 								
															 | 
						
External Databases (Donor) | 
						|
| BioSamples | SAMEA115396858 | 
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes | 
| Was the consent voluntarily given? | Yes | 
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes | 
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No | 
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes | 
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised | 
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes | 
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No | 
| How may genetic information associated with the cell line be accessed? | Controlled Access | 
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No | 
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes | 
| Name of accrediting authority involved? | Ethics Committee of the RIKEN BioResource Research Center Ethics Committee of the medical hospital of Chiba University | 
| Approval number | No. Tsukuba 29–3 and No. HS202109-04 | 
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | 
hIPSC Derivation
General | 
						|
| Source cell type | 
										
				
	
			 A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes. 
	
			Synonyms 
		
  | 
							
Reprogramming method | 
						|
| Vector type | Non-integrating | 
| Vector | Sendai virus | 
| Genes | |
| Is reprogramming vector detectable? | 
										 No 									 | 
								
| Notes on reprogramming vector detection | GFP fluorescence | 
Vector free reprogramming | 
						|
Other | 
						|
| Derived under xeno-free conditions | 
								 Unknown 							 | 
						
| Derived under GMP? | 
								 Unknown 							 | 
						
| Available as clinical grade? | 
								 Unknown 							 | 
						
Culture Conditions
| Surface coating | Laminin | 
| Feeder cells | 
															 No 														 | 
						
| Passage method | 
								Enzyme-free cell dissociation
								
																											 
											EDTA										 
																	
							 | 
						
| Medium | 
								Other medium:		 
			Base medium: StemFit AK02N			 
				
		
								Main protein source: StemFit Supplement B and C Serum concentration: 0 %  | 
						
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes  | 
					
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes  | 
					
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes  | 
					
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| NANOG | 
											 Yes 						                 | 
																                
						                |||||
| POU5F1 (OCT-4) | 
											 Yes 						                 | 
																                
						                
Morphology pictures
HiPS-RTT.CUH01_x20_01.tif
Scale bar: 100 µm
Differentiation Potency
In vitro spontaneous differentiation
					Morphology
1_Overlay.tif
Blue: DAPI, Green: AFP, Red: FOXA2, scale bar: 100 µm
In vitro spontaneous differentiation
					Morphology
1_Overlay.tif
Blue: DAPI, Green: SMA, Red: HAND1, scale bar: 100 µm
In vitro spontaneous differentiation
					Morphology
1_Overlay.tif
Blue: DAPI, Green: TUJ1, Red: PAX6, scale bar: 100 µm
Microbiology / Virus Screening | 
						|
| HIV 1 | Negative | 
| HIV 2 | Negative | 
| Hepatitis B | Negative | 
| Hepatitis C | Negative | 
| Mycoplasma | Negative | 
Genotyping
Karyotyping (Cell Line) | 
					|
| Has the cell line karyotype been analysed? | 
								 Yes 								
																	
												46 XX
											 
																				
																															
											Passage number: 4											 
																															
											Karyotyping method:
											Array CGH											
																						 
																			 | 
						
Other Genotyping (Cell Line) | 
					|

Login to share your feedback, experiences or results with the research community.